Cascade Technologies Corp. (OTCBB: CSDT) announced today that Robert Chave, an experienced designer and developer of precision instruments with optical elements requiring high levels of precision in extreme circumstances of deployment, was appointed as the company’s Chief Technologist.
During his 15 years at the Jet Propulsion Laboratory (JPL), Robert Chave designed and developed instruments and sub-systems with opto-mechanical elements for the Mars Rovers, the James Webb and Hubble Space telescopes, and a U2 aircraft-based spectrometer for monitoring ozone degradation above the earth’s poles.
“Robert’s general talents and specific expertise are exceptionally well-suited for our research and development needs,” said Dr. Farkas, Chairman and CEO of Cascade Technologies Corp. “We feel fortunate that he is highly interested in the emerging field of advanced biomedical optical imaging. Having two JPL veterans as our Chief Scientist (Dr. Greg Bearman) and now Chief Technologist, respectively, puts us in a privileged position to build the unique medical devices enabling the exciting clinical applications we pursue,” continued Dr. Farkas.
Mr. Chave has a substantial record of achievement in advanced engineering. While at JPL, he was principal investigator on a NASA Advanced Technology Development Grant in Low Temperature Science and Engineering. This research led to the invention of a magnetostrictive super-fluid helium valve, linear and rotary low temperature actuators and related tools with significance for condensed matter physics, astronomy and cryosurgery. Robert was Visiting Research Faculty in the Department of Materials Science at Caltech. This work lead to 12 NASA New Technology awards to him personally and over 20 awards to authors on the project in total. In 2000 he founded RCAppP Inc., a contract design firm that designs, builds and calibrates instruments for clients and end users who have included the Office of Naval Research, the U.S. Departments of Energy, Defense, and Homeland Security, NASA, Los Alamos National Laboratories, Caltech, and the Smithsonian Observatory, as well as private corporations, such as the Idealabs family of companies.
Robert received his BSME, magna cum laude, from Tufts University; and an MSME in engineering design and material science, through the Polymer Processing Program at the Laboratory at MIT. Robert also worked in software development for robot kinematics at the Technical University of Berlin, and did contract research for Mettler Instrument (CH) at Stanford’s Design Division. He is the author of patents and articles on numerous devices involving advanced technologies, and is active with the Optical Society of Southern California and the Society of Photo-Optical Instrumentation Engineers (SPIE).
About Cascade Technologies Corporation
Cascade Technologies Corp., through its wholly-owned subsidiary Spectral Molecular Imaging, Inc. (SMI), is a development-stage medical imaging device company, applying its proprietary hyperspectral-optical imaging technology—originally developed for satellite reconnaissance—to advance the early and accurate diagnoses of cancer and precancerous conditions. SMI is developing non-invasive, high-resolution optical imaging systems using its patented technology and other proprietary knowhow for improved clinical diagnostics, primarily in the field of cancer pathology, by identification and analysis of certain molecular, cellular, and tissue features via hyperspectral-imaging approaches. We expect to provide services related to our primary products, including software modules and maintenance services, and to develop optical diagnostic products that operate in conjunction with surgical and/or evaluation procedures in real time. We believe that our technology will enable early detection and more reliable diagnosis of various diseases, such as melanoma, Barrett’s esophagus (a condition caused by chronic acid reflux that can lead to esophageal cancer) and lung cancer. We expect that medical devices using or based on our developed technology can significantly improve long-term patient outcomes and may substantially reduce overall costs for the healthcare system. For more information, please visit http://www.spectralmi.com.
This news announcement contains or may contain certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, without limitation, statements regarding SMI's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. Such forward-looking statements are subject to significant risks and uncertainties, including those detailed in filings made by Cascade Technologies Corp., SMI's parent, with the Securities and Exchange Commission. Accordingly we caution our readers that actual results may differ materially from our beliefs or expectations due to economic, business, competitive, market and regulatory factors. We assume no obligation or undertaking to update any forward-looking statements to reflect any changes in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. You should, however, review additional disclosures we make in the reports filed with the Securities and Exchange Commission.
Daniel L. Farkas, Ph.D.